Follow
Emiliano Calvo
Emiliano Calvo
START Madrid-HM CIOCC
Verified email at startmadrid.com
Title
Cited by
Cited by
Year
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ...
The Lancet Oncology 17 (7), 883-895, 2016
12792016
Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer
MD Hellmann, MK Callahan, MM Awad, E Calvo, PA Ascierto, A Atmaca, ...
Cancer cell 33 (5), 853-861. e4, 2018
8022018
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ...
The lancet oncology 17 (11), 1590-1598, 2016
7242016
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
6662018
Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
J Tabernero, F Rojo, E Calvo, H Burris, I Judson, K Hazell, E Martinelli, ...
Journal of Clinical Oncology 26 (10), 1603-1610, 2008
6372008
CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer
YY Janjigian, J Bendell, E Calvo, JW Kim, PA Ascierto, P Sharma, PA Ott, ...
Journal of Clinical Oncology 36 (28), 2836, 2018
5612018
Phase I dose-escalation study of JNJ-42756493, an oral pan–fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
J Tabernero, R Bahleda, R Dienstmann, JR Infante, A Mita, A Italiano, ...
Journal of Clinical Oncology 33 (30), 3401-3408, 2015
3882015
Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial
RW Naumann, A Hollebecque, T Meyer, MJ Devlin, A Oaknin, J Kerger, ...
Journal of Clinical Oncology 37 (31), 2825, 2019
3352019
Clinical challenges of immune checkpoint inhibitors
M de Miguel, E Calvo
Cancer cell 38 (3), 326-333, 2020
3282020
Principles of oncologic pharmacotherapy
CH Takimoto, E Calvo
Cancer management: a multidisciplinary approach 11, 1-9, 2008
2932008
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma
DA White, P Camus, M Endo, B Escudier, E Calvo, H Akaza, H Uemura, ...
American journal of respiratory and critical care medicine 182 (3), 396-403, 2010
2512010
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma
J Rodon, MA Carducci, JM Sepulveda-Sánchez, A Azaro, E Calvo, ...
Clinical Cancer Research 21 (3), 553-560, 2015
2462015
Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort
NE Ready, PA Ott, MD Hellmann, J Zugazagoitia, CL Hann, F de Braud, ...
Journal of Thoracic Oncology 15 (3), 426-435, 2020
2372020
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a …
RS Herbst, HT Arkenau, R Santana-Davila, E Calvo, L Paz-Ares, ...
The Lancet Oncology 20 (8), 1109-1123, 2019
2302019
Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors
R Bahleda, A Italiano, C Hierro, A Mita, A Cervantes, N Chan, M Awad, ...
Clinical cancer research 25 (16), 4888-4897, 2019
2172019
Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results
P Sharma, A Siefker-Radtke, F de Braud, U Basso, E Calvo, P Bono, ...
Journal of Clinical Oncology 37 (19), 1608, 2019
2052019
Carlumab, an anti-CC chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label …
I Brana, A Calles, PM LoRusso, LK Yee, TA Puchalski, S Seetharam, ...
Targeted oncology 10, 111-123, 2015
1992015
Phase I study of the indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors
KH Jung, P LoRusso, H Burris, M Gordon, YJ Bang, MD Hellmann, ...
Clinical Cancer Research 25 (11), 3220-3228, 2019
1972019
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer
J Cortes, J Rodriguez, JM Aramendia, E Salgado, A Gurpide, ...
Oncology 64 (1), 28-35, 2002
1842002
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors
E Calvo, J Baselga
Journal of Clinical Oncology 24 (14), 2158-2163, 2006
1772006
The system can't perform the operation now. Try again later.
Articles 1–20